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Automated planar patch clamp systems are widely used in drug evaluation studies because of their ability to
provide accurate, reliable, and reproducible data in a high-throughput manner. Typically, CHO and HEK
tumorigenic cell lines overexpressing single ion channels are used since they can be harvested as high-density,
homogenous, single-cell suspensions. While human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)
are physiologically more relevant, these cells are fragile, have complex culture requirements, are inherently
heterogeneous, and are expensive to produce, which has restricted their use on automated patch clamp (APC)
devices. Here, we used high efficiency differentiation protocols to produce cardiomyocytes from six different
hPSC lines for analysis on the Patchliner (Nanion Technologies GmbH) APC platform. We developed a two-
step cell preparation protocol that yielded cell catch rates and whole-cell breakthroughs of*80%, with*40%
of these cells allowing electrical activity to be recorded. The protocol permitted formation of long-lasting
(>15min), high quality seals (>2GO) in both voltage- and current-clamp modes. This enabled density of
sodium, calcium, and potassium currents to be evaluated, along with dose–response curves to their respective
channel inhibitors, tetrodotoxin, nifedipine, and E-4031. Thus, we show the feasibility of using the Patchliner
platform for automated evaluation of the electrophysiology and pharmacology of hPSC-CMs, which will enable
considerable increase in throughput for reliable and efficient drug evaluation.
Introduction
Pharmaceutical drug development is costly and time-consuming, with an average drug development duration of
10–15 years [1] and costs upward of a billion dollars [2]. Fur-
thermore, between 1980 and 2009, approximately one in seven
licensed drugs that had demonstrated sufficient efficacies in
Phase III trials had to be withdrawn from the market for reasons
including unanticipated side effects like cardiotoxicity, hepa-
totoxicity, and gastrointestinal issues [3]. Unexpected cardio-
toxic side effects have been implicated in 28% of drug
withdrawals in the United States [4]. It has been calculated that
reducing drug attrition by 5% in Phase I clinical development
can reduce drug development costs by 5.5%–7.1% [5], equating
to savings of about $100 million for drug developers [6]. This
has necessitated the development of various in vitro, ex vivo,
and/or preclinical models to predict toxicity in humans at earlier
stages of the drug development pipeline.
Phase I drug trials are commonly carried out in aneuploid
tumor cell lines (eg, CHO or HEK cells) that have been ge-
netically engineered to overexpress an ion channel of choice.
However, they cannot replicate the complexity of the working
cardiomyocyte, and consequently, multi-channel blocking
drugs that are considered safe and ‘‘QT-neutral,’’ such as
verapamil (dual blocking of potassium IKr and calcium ICa,L
channels) are flagged as potentially harmful in the single ion
channel assays [7]. Though ex vivo systems, such as ventric-
ular wedge preparations [8] and Purkinje fibers [9], have been
extensively used in physiological and pharmacological stud-
ies, their low-throughput nature and inter-species differences
limit their suitability as drug screening assays. Use of animals
is also not in line with the growing expectation in many
countries to address the 3Rs of animal-based research (re-
finement, reduction, and replacement of animals) [10].
As an example of these issues, the mouse heart beats
*10 times faster than the human heart and does not utilize
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the IKr (HERG) potassium channel, which is important in
repolarization in human cardiomyocytes [11]. The down-
stream effects of mutations or drugs implicated in cardiac
arrhythmias would ideally be studied in a primary human
cardiomyocyte. However, use of such cells as large-scale
pharmaceutical screens is hindered by their limited avail-
ability, poor consistency, limited proliferation, and almost
immediate de-differentiation in culture [6].
Cardiomyocytes derived from human pluripotent stem cells
(hPSC-CMs), comprising human embryonic stem cells (hESCs)
and human induced pluripotent stem cells (hiPSCs), are now
emerging as a viable alternative for drug safety testing (for re-
views on the subject refer to [12,13]). Technology improve-
ments over the last decade now allow rapid, cost-effective
production of hPSC-CMs at purities that exceed 70% [14].
Even though hPSC-CMs have a relatively immature phe-
notype, they have shown faithful pharmacological responses
to over 60 different compounds that include modulators of
ion channels, b (1-, and 2-) receptors, and muscarinic re-
ceptors [6]. A blinded study that measured the effects of 12
cardiac and non-cardiac drugs over a 6-log dose–response
range, covering estimated unbound therapeutic plasma con-
centrations, showed a close association between data ob-
tained from hPSC-CMs and the clinic [15]. Work from
GlaxoSmithKline that cross-compared the pharmacological
responses of hPSC-CMs and animal models concluded that
the human cells offered a reliable and cost-effective surrogate
to preclinical in vitro testing [16]. hPSC-CMs were also used
to show that the anticancer drug doxorubicin, delivered via an
HER2-targeted liposomal pathway, reduced the cardiotoxicty
observed with anthracyclines, which assisted the decision to
advance the drug to Phase I testing [17].
To date, patient-specific hiPSC-CMs have been used to
evaluate altered phenotype and drug rescue of various chan-
nelopathies affecting the heart, including Long QT syndrome
(LQTS) 1 [18], 2 [19–22], 3 [23], 8, [24], and catecholami-
nergic polymorphic ventricular tachycardia (CPVT) [25,26].
Notably, Terrenoire et al. performed multi-parameter in vitro
drug testing on the hPSC-CMs of a patient with complex
LQTS to arrive upon a combinatorial regime that proved ef-
fective for the patient in the clinic, thus demonstrating the use
of hPSC-CMs in personalized medicine [27]. Collectively, such
studies have led the CIPA initiative (Comprehensive In Vitro
Proarrhythmia Assay) to propose the integration of hPSC-CMs
into the ICH (International Conference on Harmonisation) S7a/
b and E14 guidelines by the end of 2015. These have been the
mainstay over the last decade of preclinical assessment of
cardiac electrophysiology for new drugs [28].
Despite these successes, virtually all studies to date have
used conventional patch clamp to evaluate the electrophysi-
ology of hPSC-CMs. Given that this approach can only
produce 10–15 data points a day [29], there is now a pressing
need for automated platforms that can produce high quality
data at a throughput relevant to industry and academia.
Automated patch clamping (APC), by allowing multiple
recordings in parallel, can increase data throughput 10- to
100-fold depending on the ion channel under investigation
and the platform used [30]. By reducing the complexity of the
process, these platforms also make patch clamping accessible
to more users, regardless of previous experience in electro-
physiology. General drawbacks of parallel patch clamping
include a requirement for high quality, high density, ho-
mogenous cell suspensions, which becomes restrictive when
using expensive, low-yielding cell types [29].
These challenges are reflected by the paucity of data
available for hPSC-CM evaluation using APCs. The PatchX-
press planar patch clamp platform has been used for the APC
analysis of INa, ICa, and IKr currents using hiPSC-CMs.
However, that study used a genetically engineered hiPSC line,
which allowed drug selection of the cardiomyocytes. Despite
using a genetically enriched near-pure population of hiPSC-
CMs, the study reported low seal rates (*50% across 58
wells) and poor seal qualities (*200MO) [31], highlighting
the need to develop better protocols for the preparation and
analysis of cells by APC.
An alternative device is the Patchliner System (Nanion
Technologies), which is a medium-throughput patch clamp
device, capable of executing up to 48 unattended recordings
and generating *500 data points a day [32]. However, Pat-
chliner recordings have typically been performed on recom-
binant HEK and CHO cell lines, which are easy to obtain in
large numbers, and form high-quality, high-density, homoge-
nous single-cell suspensions ideal for APC (Table 1). In con-
trast, hPSC-CMs provide more physiologically relevant model
systems for drug efficacy and safety testing (Table 1), but these
are expensive to produce in large numbers and very sensitive
to enzymatic processing into single-cell suspensions [6].
In this report we used high efficiency differentiation pro-
tocols that do not require genetic selection to produce hPSC-
CMs of purities in excess of 80% to enable optimization of
the Nanion Patchliner automated planar patch clamp system
across cardiomyocytes derived from six hPSC lines that in-
clude three healthy lines (one hESC; two hiPSC) and three
hiPSC lines harboring disease-causing mutations (one CPVT;
two Duchenne muscular dystrophy [DMD]). We developed a
two-step cell preparation protocol that proved effective in
enabling catch rates of 81.25%– 6.68%, seal rates of
79.68%– 7.06%, and seal qualities of up to >2GO. Analysis
in voltage clamp mode allowed evaluation of INa, ICa,L, and
IK current densities, and the impact on these currents of their
respective blockers tetrodotoxin (TTX), nifedipine, and E-
4031. Thus, this work paves the way to use APC for high-
throughput analysis of the electrophysiology and pharma-
cology of hPSC-CMs.
Materials and Methods
Isolation of fibroblasts from patient skin biopsies
Skin punch biopsies of 4mm were transported from the
clinic into the laboratory in Transport medium (Table 2) and
washed thrice in the same, after which they were transferred
into bacterial-grade Petri dishes. Using sterile forceps and
scalpels, the samples were cleaned off any adipose and epi-
dermal tissue, minced into 1mm pieces and then digested—
first with 2.5% trypsin (Invitrogen) for 20min, and then with
1mg/mL collagenase IV (Invitrogen) for 90min, both at
37C. The digested cells were spun down at 200 g for 5min,
plated in Chang’s D medium (Table 2), and grown for 2–3
weeks until confluent, with medium changes every 3–4 days.
Generation of patient-specific hiPSCs
The protocol followed for the generation of hiPSCs was
based on a previously published method [33], and media
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formulations are as detailed in Table 2. In brief, on the day of
transduction, fibroblasts were seeded into tissue culture-
treated six-well plates in fibroblast medium, at a density of
50,000 cells/well. Once the cells had adhered to the plastic
(after 5–6 h), they were infected with streptavidin-conjugated
viral particles expressing OCT4, NANOG, SOX2, and LIN28,
in the presence of 8mg/mL of Polybrene (Sigma-Aldrich) at a
multiplicity-of-infection of 10. Twenty-four hours post-
transduction (p.td), the cells were washed twice with PBS and
fed with fresh fibroblast medium. Forty-eight hours p.td., the
cells were harvested using 0.05% trypsin (Invitrogen), re-
suspended in hPSC media supplemented with 10ng/mL FGF
(Peprotech), and transferred to tissue culture treated 90mm
Petri dishes containing mitomycin-C inactivated mouse em-
bryonic fibroblasts (MEFs) at a density of 1.8· 106 cells/well.
For the first week, cells were maintained in hPSC medium
containing 10 ng/mL FGF, after which the medium was
switched to MEF-conditioned hPSC medium supplemented
with 10 ng/mL FGF. In either case, medium changes were
performed daily until around day 25-day 30 p.td.
Cardiac differentiation of hiPSCs
Embryoid body-mediated differentiation. The protocol fol-
lowed was based on a previously published protocol [34],
and all media formulations are detailed in Table 2. In brief,
on day 0 of differentiation, embryoid body (EB) formation
was initiated by the seeding of hPSCs into 96-well V-
bottomed plates (Thermo Scientific), at a density of 6,000
cells/well, in RIP medium. On day 2, the RIP medium was
replaced with RD medium. On day 4, the EBs were trans-
ferred into 96-well U-bottomed tissue culture-treated plates
(Fisher Scientific) and maintained in RB medium from
thereon, with medium changes every 3–4 days. Sponta-
neously beating clusters were observed from day 8 onward.
Table 1. A Comparison of the Relevance of Recombinant Cell Lines and Human
Stem Cell-Derived Cardiomyocytes for Drug Screening and Development
Attributes Recombinant cell lines Stem cell-derived cardiomyocytes
Cell line generation
Ease of production Easy to grow; undergo prolonged, high-density
proliferation in culture; high capacity for
stable recombinant protein expression
Require specialist know-how and
reagents; limited proliferation
in culture; low capacity for stable
recombinant protein expression
Cost of production *£5/L of culture media *£400/L of culture media
Cell preparation for planar patch clamp
Homogeneity of prep Homogeneous Heterogeneous
Clumpiness of prep Single cell A mixture of single cells,
cell clusters, and debris
Quality of seals >1GO 200MO–1GO
Quality/relevance of data
Cell shape Round Varied
Membrane capacitance <10 pF for HEK293 *25 pF [29]
Multi-ion channel phenotype No Yes
Contractile machinery No Yes
Upstroke velocity *400 dV/dt [47] *17 dV/dt [45]
RMP -40mV [47] *60mV [45]
Maximal peak INa -264– 34 pA/pF [47] -216.7– 18.7 pA/pF [29]
Maximal peak ICa,L 600 pA/pF [47] -17.1 – 1.7 pA/pF [29]
Peak IKr tail current 12.8 – 1.6 pA/pF [48] 0.95 – 0.02 pA/pF [29]
RMP, resting membrane potential.
Table 2. Media Formulations for Stem Cell
Derivation, Culture, and Differentiation
Acronym Component Conc. Supplier
Transport
media
HBSS (10·) 10% Invitrogen
H2O 88% Sigma-Aldrich
Pen/strep 1% Invitrogen
Fungizone 1% Invitrogen
Chang’s
D media
Chang’s D 98% Invitrogen
L-glutamine 2mM Invitrogen
HEPES 100mM Invitrogen
Pen/strep 1% Invitrogen
Fungizone 1% Invitrogen
Fibroblast media 1· DMEM 78% Invitrogen
FBS 20% Perbio
NEAA 1% Invitrogen
L-glutamine 1% Invitrogen
b-mercaptoethanol 100 mM Sigma-Aldrich
hPSC media DMEM F12 83% Invitrogen
KSR 15% Invitrogen
NEAA 1% Invitrogen
GlutaMAX 1% Invitrogen
b-mercaptoethanol 100 mM Sigma-Aldrich
bFGF 8 ng/mL R&D
RIP media 1· RPMI 98% Invitrogen
ITS 1% Gibco
Chemically
defined lipid
1% Gibco
1-Thioglycerol 400 mM Sigma-Aldrich
PVA 4mg/mL Sigma-Aldrich
bFGF 6 ng/mL Peprotech
BMP4 20 ng/mL R&D
RD media 1· RPMI 80% Invitrogen
FBS 20% Perbio
1-Thioglycerol 400 mM Sigma-Aldrich
RB media 1· RPMI 98% Invitrogen
50· B-27
supplement
2% Invitrogen
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Monolayer-mediated differentiation. Undifferentiated hPSCs
were seeded onto Matrigel-coated dishes at a density of
1 · 105 cells/cm2, and allowed to expand for 72 h until
confluent. At this stage, (day 1 of differentiation) cells were
treated with medium A consisting of StemPro-34 (Life
Technologies) medium, recombinant human Activin A (Life
Technologies) and recombinant human BMP4 (R&D Sys-
tems). Media exchange was performed on day 3 with medium
B- consisting of RPMI base medium (Life Technologies)
supplemented with 1· B-27 (Life Technologies) and a small
molecule inhibitor, KY02111 (R&D Systems). From day 5
onward, cells were maintained in RPMI base medium sup-
plemented with B-27 only, and media changes were per-
formed every 2–3 days.
Electrophysiology
Manual patch clamp was performed using an ECP-10
HEKA amplifier. Cells were maintained in NT Buffer and at
37C during recordings. Patch pipettes were pulled on a
Sutter P-97 programmable micropipette puller and had re-
sistances of between 2 and 5MO when filled with ionic so-
lution. Data were recorded using the Pulse software (HEKA)
and analyzed using Clampfit v9.0 (Molecular Devices).
Automated electrophysiological analysis of the hPSC-
CMs was performed on an NPC-16 Patchliner Octo platform
(Nanion Technologies) fitted with two EPC-10 quadro am-
plifiers (HEKA Elektronik GmBH) using disposable boro-
silicate glass chips (Nanion Technologies). When filled with
intracellular solution the chip resistance was between 1.8–
3MO. Data were acquired using the Patchmaster software
(HEKA Elektronik GmBH) analyzed offline using IGOR-
Pro (WaveMetrics, Inc.).
Patch clamp solutions
Internal solutions for (1) voltage-gated Na and Ca channel
recordings: 50mM CsCl, 10mM NaCl, 60mM CsF, 20mM
EGTA, 10mM HEPES, CsOH pH 7.2, osmolarity
285mOsmol; (2) voltage-gated K channel recordings: 50mM
KCl, 10mM NaCl, 60mM KF, 20mM EGTA, 10mM
HEPES, KOH pH 7.2, osmolarity 285mOsmol; (3) action
potential (AP) recordings: 145mM KCl, 5mM NaCl, 2mM
CaCl2, 2mM MgCl2, 4mM ethylene glycol tetra-acetic acid,
10mM HEPES, KOH pH 7.3. External solutions for (1)
voltage-gated K and Na channel recordings: 140mM NaCl,
4mM KCl, 1mM MgCl2, 2mM CaCl2, 5mM D-glucose
monohydrate, 10mM HEPES, NaOH pH 7.4, osmolarity
298mOsmol; (2) voltage-gated Ca channel recordings:
125mM TEA-Cl, 20mM BaCl2, 10mM D-glucose mono-
hydrate, 10mM HEPES/TEA OH pH 7.35, osmolarity: 300–
305mOsmol; (3) AP recordings: 140mM NaCl, 4mM KCl,
1mM MgCl2, 1.8mM CaCl2, 10mM D-glucose mono-
hydrate, 10mM HEPES; Seal enhancer: 80mM NaCl, 3mM
KCl, 10mM MgCl2, 35mM CaCl2, 10mM HEPES (Na
+-
salt), HCl pH 7.4, osmolarity: 298mOsmol
Ethics
This study conformed to the principles outlined in the
Declaration of Helsinki. All subjects gave informed consent
for blood testing for genetic abnormalities associated with
hereditary cardiac channelopathies, and for tissue donation.
Isolation and use of patient fibroblasts was approved by the
Nottingham Research Ethics Committee (Approval 09/H0408/
74), and sample collections are registered with the U.K.
Clinical Research Network under IRAS project ID24624.
Isolation and use of patient dental pulps were also performed
with full patient consent and ethical approval (LREC 180808/
HR/12).
Statistics
Statistical significance was determined by Student’s t-
tests, or ANOVA with Tukey post-hoc tests for pairwise
comparisons (MS Excel 2010). Data were considered sig-
nificant where P < 0.05. Results are presented as mean val-
ues – standard error of mean; n denotes the number of cells
in which measurements were made.
Results
Generation and characterization of hPSC-CMs
Two healthy hiPSC lines [HUES7-fibroblast-derived
FIB-hiPSC and dental pulp-derived BT1-hiPSC], and three
diseased hiPSC lines (DMD-afflicted DMD4- and DMD16-
hiPSCs and CPVT-afflicted CP1-hiPSCs) were generated in
vitro by lentiviral delivery of the OCT4, NANOG, SOX2, and
LIN28 reprogramming factors. These putative hiPSC lines
were measured against internationally accepted pluripotency
criteria to establish their phenotype [35].
Karyotypic analyses revealed that the cells were geneti-
cally stable with a normal complement of 46XY or 46XX
chromosomes (Fig. 1C), and their population doubling times
were similar to those of HUES7 hESCs (Fig. 1A). RT-PCR
analysis demonstrated that the hiPSCs had reactivated the
reprogramming factors OCT4, NANOG, SOX2, and LIN28 at
their endogenous loci, and silenced the lentiviral transgenes
(Fig. 1B and Supplementary Fig. S1; Supplementary Data
are available online at www.liebertpub.com/scd). Im-
munostaining confirmed that the hiPSCs had silenced the
fibroblast-specific marker FSA; and reactivated the plur-
ipotency markers TRA-1-81, SSEA-4, OCT4, and LIN28
(Supplementary Fig. S2). Flow cytometry further confirmed
that the hiPSCs had silenced the differentiation marker
SSEA-1; and reactivated the pluripotency marker SSEA-4
(Fig. 1D and Supplementary Fig. S3). These results con-
firmed the pluripotent nature of the five iPSC lines.
To generate human cardiomyocytes in vitro, these five
hiPSC lines along with a HUES7 hESC control were
differentiated via the embryoid-body and monolayer-routes
(Supplementary Videos S1 and S2). The presence of cardiac-
specific proteins and their spatial organization within the
hPSC-CMs were determined by dissociating the beating clus-
ters/sheets and staining the dispersed cells with immunofluo-
rescent cardiac a-actinin and cardiac troponin T (cTnT)
antibodies (Fig. 2A, B andSupplementary Figs. S4 and S5).All
six lines produced hPSC-CMs with similar morphologies and
patterns ofmyofilament organization.While cTnT appeared as
longitudinal, punctuate, fibrous striations, a hallmark of func-
tional cardiomyocytes, a-actinin appeared homogenously
throughout the cell as longitudinal fibrous striations. The
hPSC-CMs had multi-angular morphologies appearing round,
elongated, branched, or triangular, with one or more oval nu-
clei. Flow cytometry analysis for the cardiac a-actinin marker
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revealed the cardiac preparations to have purities of
91.2%– 1.4% (Fig. 2C and Supplementary Fig. S6).
To assess the electrophysiological functionality of the
hPSC-CMs, beating clusters or monolayers of cardiomyo-
cytes were disaggregated into single cells, seeded onto Mat-
Tek dishes, and analyzed by whole-cell patch clamp. The APs
recorded from these cells demonstrated, on average, AP du-
ration (APD), APD50 (APD at 50% of the repolarisation
curve), APD90 (APD at 90% of the repolarization curve), AP
amplitude (APA), resting membrane potential (RMP), and
upstroke velocity values of 394.9– 27.6ms, 106.7– 12.2ms,
154.9– 15.7ms, 55.8– 4.1mV, -33.2– 3.4mV, and 6.3–
1.5V/s respectively. Table 3 lists the specific values obtained
for the AP waveforms of HUES7- (n= 58), FIB-iPS- (n= 44),
and BT1-iPS (n= 29)-derived cardiomyocytes.
The APD90/APD50 ratio, which describes the shape of the
repolarization curve, was used to determine the specific
subtype of each hPSC-CM analyzed. hPSC-CMs with low
APD90/APD50 ratios (£1.3, indicative of a pronounced pla-
teau phase) were classified as ventricular-like, while those
with high APD90/APD50 ratios (‡1.8, indicative of fast
phase-I repolarization) were classified as atrial-like. Cardi-
omyocytes with AP characteristics intermediary to those of
the atrial-like and ventricular-like cells, and APD90/APD50
ratios between 1.4 and 1.7 were classified as nodal-like [20].
The HUES7, FIB-iPS, and BT1-iPS lines all produced car-
diomyocytes of atrial-like, ventricular-like, and nodal-like
morphologies (Table 3), with representative traces shown in
Fig. 2D.
Thus, the structural and electrophysiological properties of
hPSC-CMs were consistent with other reports describing
these cells, which permitted their use in development of
protocols for automated electrophysiology analysis.
Development of a cell harvesting protocol
compatible with automated planar patch clamp
As with any planar patch clamp platform, the Patchliner
requires freshly dissociated single cells in suspension. To
achieve this, intact clusters or monolayers of hPSC-CMs of
91.2%– 1.4% purity (Fig. 2C and Supplementary Fig. S6)
were dissociated into single cells using a trypsin-containing
cell dissociation solution at 37C (Fig. 3A). Trypsin was
included in the dissociation solution as it was the only en-
zyme we found capable of breaking the tightly clustered
cardiomyocytes within EBs and monolayers into single
FIG. 1. Characterization of hiPSC lines. (A) PDs at each passage were calculated using the formula [log10 (total cell
counts/cells seeded)/log10 (2)], where the cell number seeded was 48,000 cells/cm2. All five iPSC lines exhibited PDs
similar to that of HUES7 hESCs, *33.5 h. (B) RT-PCR analysis of OCT4, NANOG, SOX2, and LIN28 expression from
endogenous ‘‘E’’ and lentiviral ‘‘L’’ loci in FIB-, BT1-, CP1-, DMD4-, and DMD16-iPS demonstrating the activation of
endogenous pluripotency genes and the silencing of lentiviral transgenes, at passage 15. (C) Representative karyograms
showing normal 46XY and 46XX karyotypes, at passage 15. (D) Representative flow cytometry data of FIB-iPSCs
demonstrating the expression of pluripotency marker SSEA-4, and the absence of differentiation marker SSEA-1. DMD,
Duchenne muscular dystrophy; FIB, HUES7-fibroblast-derived; hESCs, human embryonic stem cells; hiPSC, human in-
duced pluripotent stem cells; PD, population doublings. Color images available online at www.liebertpub.com/scd
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cells. Other ‘‘gentler’’ enzymes like accutase, collagenase,
and dispase produced cell clumps that were unsuitable for
planar patch clamp (Fig. 3B). However, when processed on
the Patchliner, trypsin-treated cells demonstrated low catch
rates of 54.16%– 11.89%, and a low incidence of conver-
sion to whole-cell breakthroughs (34.72% – 8.17%). Fur-
thermore, only 8.33%– 4.7% of the cells that were
successfully patched exhibited functional currents (Table 4).
The cardiac differentiation of hPSCs is a costly, time-
consuming, and labor-intensive process, and the derived
cardiomyocytes are fragile, highly sensitive to the environ-
ment, and characterized by low (ie, physiological) levels of
endogenous ion channel expression (Table 1). To minimize
cell wastage and improve the productivity of the Patchliner,
we set about developing a cell preparation protocol that
allowed optimal use of our hPSC-CMs on the Patchliner.
Reasoning that the inclusion of trypsin was damaging the
cell membrane [36] and reducing the density of functional
ion channels, we evaluated whether hPSC-CMs could be
successfully prepared by mechanical dissection using a stem
cell knife, a commercially available glass capillary with a
200 mm bore, and a sharpened 45 cutting edge. However,
FIG. 2. Characterization of hiPSC-derived cardiomyocytes (hiPSC-CMs). Representative immunofluorescence images of
HUES7-cardiomyocytes showing positive (A) cardiac a-actinin, and (B) cardiac troponin T staining highlighting charac-
teristic cardiac muscle striations. Scale bars represent 32mm. (C) Representative flow cytometry data of HUES7-CMs
demonstrating cardiac purities of 91.2%– 1.4% (Supplementary Fig. S6). (D) Representative AP traces demonstrating the
formation of atrial-like, ventricular-like, and nodal-like cardiomyocytes. The classification of different cardiac cell types
was based on the APD90/APD50 ratio. APD90/50 values £1.4 were designated as ventricular-like, 1.4–1.7 were designated
as nodal-like, and ‡1.7 were designated as atrial-like. AP, action potential. Color images available online at www
.liebertpub.com/scd
Table 3. Action Potential Parameters of Human Pluripotent Stem Cell-Cardiomyocytes
as Determined by Manual Patch Clamp
Cell type Cell line Cslow (pF) RMP (mV) APA (mV)
Upstroke
velocity (V/s) APD (ms) APD50 (ms) APD90 (ms)
Atrial-like HUES7 34.1 – 11.1 -29.2– 14 44.9 – 7.1 5.6 – 10.9 429.3 – 2.3 84.7– 4.5 165.2– 3.5
FIB-iPS 26.5 – 5.1 -35.23– 2.4 44.5 – 4.2 5.9 – 1.6 518 – 129.3 105.3– 27.9 192.3– 48.8
BT1-iPS 29.2 – 5.9 -22.3– 1 35.1 – 3.8 2.5 – 0.5 379.1 – 42.9 49.4– 7.6 95– 16.1
Ventricu
lar-like
HUES7 19.4 – 4.3 -36.2– 3 68.8 – 5.8 1.9 – 0.5 327.2 – 18.1 120.3– 10.3 149.8– 10.5
FIB-iPS 14.8 – 3.8 -53.3– 5.1 62.7 – 3.7 13.3 – 3.7 336.3 – 50 158.5– 27.3 127.3– 22.3
BT1-iPS 21.8 – 4 -25.4– 2.9 69.7 – 4 12.1 – 2.4 252.5 – 21 59.8– 4.5 77.7 – 6
Nodal-like HUES7 29.8 – 5.5 -23.1– 2.3 63.5 – 3.7 9.9 – 2 447.4 – 24.6 115.5– 7.7 183.6– 12.2
FIB-iPS 10.2 – 1.6 -42.5– 3.8 50.4 – 5.9 3.2 – 0.9 479.3 – 100.8 145.9– 30.4 220.9– 46.1
BT1-iPS 14.6 – 2 -31.9– 3.1 62.4 – 8.3 1.9 – 0.4 384.6 – 86.4 121.1– 52.6 182– 78.5
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while this approach broke the cardiomyocyte clusters into
clumps, it did not yield single cells (Fig. 3C). When these
‘‘minced’’ cell preparations were run on the Patchliner, the
clumps blocked the holes of the planar chip preventing any
successful recordings (Table 4). As an alternative, we tested
a trypsin-including cold dissociation protocol [37] to try and
better preserve the integrity of the cell membranes. While
this method improved catch rates to 69.44%– 10.85%, the
single cells patched showed little to no currents, suggesting
that channel degradation due to enzymatic treatment still
remained an issue (Table 4).
To evolve the protocol further,we separated the dissociation
protocol into two steps. At least 1 week before use on the
Patchliner, hPSC-CM cultures were dispersed with trypsin-
containing cell dissociation solution. This relatively harsh
treatment produced a single-cell suspension of hPSC-CMs that
FIG. 3. Development of a cell harvesting method compatible with automated planar patch clamp. (A) The dissociation of
intact embryoid bodies or monolayers with trypsin produced single cells with little/no currents (Table 4); Collagenase/
accutase/dispase treatment (B) and mechanical dissociation protocols (C) produced cell clumps unsuitable for efficient
planar patch clamping. (E) The two-step cell dissociation protocol presented in the study produced (D) single cells with
functional currents suitable for efficient analysis of hPSC-CMs on the Patchliner. (F) Shown are the raw current traces on a
chip where 100% catch rates and whole-cell breakthroughs were achieved with HUES7 hESC-CMs using the newly
developed two-step cell dissociation protocol (E). hPSC-CMs, human pluripotent stem cell-derived cardiomyocytes. Color
images available online at www.liebertpub.com/scd
Table 4. Development of a Cell Harvest Protocol Optimal for Analysis on the Patchliner
Protocol
% catch
rate
%
whole-cell
% cells
showing APs
or currents Cell quality Comments
Trypsin-containing
solution
54 – 12 35 – 8 8– 5 Single cells (Fig. 3A) Enzyme treatment damaging cells
Mechanical dissection — — Cell clusters and
debris (Fig. 3C)
No single cells and cell clumps/
debris clogging wells
Cold dissociation 69 – 11 58 – 10 5– 2 Single cells Better cell viability and membrane
integrity, but no currents
Two-step protocol 81 – 7 80 – 7 31– 6 Single cells (Fig. 3D) Gentler the enzyme treatment
on the day of analysis, better
the quality of the recordings
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could be reseeded at a low density onto gelatine-coated tissue
culture plastic, with cells recovering their ability to beat
spontaneouslywithin 3 days of the procedure.Aweek after this
preseeding step, hPSC-CMs were reharvested using a gentle
accutase-assisted cold dissociation protocol to produce a
single-cell suspension thatwas used immediately for Patchliner
analysis (Fig. 3D). Relative to the earlier approaches used, this
two-step method yielded significant (P<0.05, n=5 in each
treatment group) improvements in catch rates (81.25%–6.68%),
whole-cell breakthroughs (79.68%–7.06%), and percentage
of cells showing APs or ionic currents (31.25% – 5.79%)
(Table 3). In some cases, all eight channels of the Patchliner
chips gave productive recordings (Fig. 3F). Therefore, this
approach to hPSC-CM preparation (Fig. 3E) was used in all
subsequent electrophysiological and pharmacological analy-
ses on the Patchliner.
Study of hPSC-CM APs by automated current-clamp
We next sought to evaluate whether the Patchliner could be
used in current clamp mode to record and measure sponta-
neous and stimulated APs from hPSC-CMs. Following the
differentiation and harvest of cardiomyocytes from the hESC
HUES7 line, spontaneous APs were recorded from the cells
under zero current clamp conditions. However, despite stable
seal properties, most cells were electrically quiescent, and
any spontaneous activity recorded was erratic and unfit for
analysis (Fig. 4A). Based on the data above (Fig. 2, Sup-
plementary Fig. S2–S6 and Table 3), this was not a cell
quality issue but rather the requirement for cells in suspension
at the time of analysis and storage at 4C before use.
To determinewhether the data quality could be improved by
pacing, preparations of HUES7-CMs were subjected to elec-
trical stimulation. An AP can only be initiated when the cell
membrane is hyperpolarized beyond a certain value called the
‘‘threshold potential,’’ which varies from cell to cell, but is
constant for a given cell at rest [38]. APs were evoked from the
HUES7-CMs by subjecting them to a train of 500ms long
depolarizing pulses (D20pA) from a holding potential of
-70mV, and analyzing their voltage responses. A depolarizing
pulse that caused an amplitude rise >30mV above RMP was
defined as the ‘‘threshold current’’ and was subsequently used
to generate APs for analysis (Fig. 4B). Using this approach we
estimated that the cells had APD90, upstroke velocity and APA
values of 231.4– 69ms, 11.9– 1.5V/s, 96.6– 7.5mV respec-
tively. Table 5 details cell line-specific values for HUES7-
(n= 14), FIB-iPS- (n= 15) and BT1-iPS (n= 13)-derived
cardiomyocytes.
To determine the effects of drug compounds on the AP
parameters of HUES7-CMs, the depolarizingNa+ current was
inhibited by the selective INa channel blocker TTX. This
caused a 1.6 – 0.4-fold decrease in APA (n = 8), which was
restored on washout with external recording solution
(Fig. 4C). Thus it was shown that the Patchliner could be used
in current clamp mode to investigate the electrophysiology
and pharmacology of hPSC-CMs, although only with pacing.
Study of hPSC-CM voltage-dependent currents
by automated voltage-clamp
The ability of the Patchliner to implement stepped de-
polarizing pulses on parallel channels gives it the potential to
carry out rapid measurement of ion channel densities. We
initially used HUES7-CMs to define the necessary protocols to
unveil INa, ICa,L, and IK currents. To record INa, 20ms long
depolarizing pulses between -70 and +40mV were applied in
10mV increments from a holding potential of-80mV. INa was
first observed at -60mV, progressively increased to reach a
maximal level at -20mV, and progressively decreased on
further depolarization (Fig. 5A). To record ICa, cells were first
held at a potential of -80mV, after which a 3s long prepulse of
-50mV was applied to voltage inactivate Na+ and any T-type
Ca+2 channels that may be present. Then, 200ms long depo-
larizing pulses between -70 and +30mV were applied in
10mV increments. ICa was first observed at -60mV, pro-
gressively increased to reach a maximal level at -30mV, and
progressively decreased on further depolarization (Fig. 5B). To
FIG. 4. Automated electrophysiological analysis of the
hPSC-CMs in current clamp mode. Representative raw data
traces of (A) spontaneous APs from HUES7-CMs showing
an erratic pattern of activity with individual spikes rarely
exceeding 20ms in duration. (B) In contrast, stimulation
protocols produced classical AP traces. Using this approach
we estimated that the cells had APD90, upstroke velocity and
APA values of 231.4 – 69ms, 11.9 – 1.5V/s, 96.6 – 7.5mV
respectively (n = 42). (C) HUES7-CMs when treated with
1 mM TTX (blocker of the fast voltage-gated sodium chan-
nel INa), showed a 1.6 – 0.4-fold reduction in AP amplitude
(n = 8), which was restored on washout with external re-
cording solution. TTX, tetrodotoxin.
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record IK, 200ms long depolarizing pulses between -60 and
+60mV were applied in 20mV increments, from a holding
potential of -80mV. IK was first observed at -40mV, and
progressively increased to reach a maximal level at +60mV
(Fig. 5C). Maximal peak INa, ICa, and IK normalized to cell
capacitance (n= 67,mean= 24.38– 2.32 pF)were 64.83– 9.11
pA/pF (n= 31, -20mV), 10.2– 2.73 pA/pF (n= 12, -30mV),
and 20.95– 3.59 pA/pF (n= 24, +40mV) respectively. V1/2
values for the same were calculated to be -34.76– 9.52mV,
-33.4– 10.2mV, and -20.6– 12.5mV respectively.
Using the parameters defined for HUES7-CMs, current–
voltage curves and current densities were determined for five
additional hPSC lines. These included hiPSC lines produced by
reprogramming embryonic fibroblasts or patient-derived dental
pulp cells from healthy individuals, or from skin fibroblasts
derived from patients carrying mutations causing CPVT and
DMD. The maximal current densities for cardiomyocytes de-
rived from these cell lines ranged from -19.6– 4.5 pA/pF to -
37.3–8.9 pA/pF, -12.8–2.4 pA/pF to -22.3– 3.3 pA/pF, and
12.2–4.1 pA/pF to 40.3–6.4 pA/pF for INa, ICa, and IK, re-
spectively (Table 6, n=5 for each cell line, Fig. 6).
Single-factor ANOVA tests were conducted across the
different lines, for each channel current. In case of the INa
current, there were significant differences in mean current
densities across the six lines at P< 0.05 [F(5,65)= 2.73,
P= 0.027]. Post hoc comparisons using the Tukey HSD test
indicated that the maximal INa current density of HUES7-CMs
was significantly different than those of cardiomyocytes de-
rived from FIB-iPS [absolute difference (ABS)= 42.33], BT1-
iPS (ABS= 27.53), CP1-iPS (ABS= 39.4), DMD4-iPS
(ABS= 31.94), and DMD16-iPS (ABS= 45.21). In case of the
ICa maximal current densities, there were no significant dif-
ferences across the HUES7-, BT1-iPS, and DMD4-iPS-
derived cardiomyocytes atP< 0.05 [F(2,10)= 1.92,P= 0.197].
Similarly, no significant differences were found in maximal IK
current densities across the six lines atP> 0.05 [F(5,54)= 2.32,
P= 0.056]. Taken together, these results suggest that the stem
cell-derived cardiomyocytes were a heterogeneous group of
cells with variable cardiac phenotypes, as has been reported by
several other research groups [39].
Efficient pharmacological screening of hPSC-CMs
by automated planar patch clamp
Next, the effects of different ion channel modulators on
hPSC-CM currents were determined using the Patchliner. In
brief, peak INa, ICa, and IK currents were measured at pulses of
-20, -30, and +40mV respectively. Steady state recordings
Table 5. Action Potential Parameters of Human Pluripotent Stem Cell-Cardiomyocytes
as Determined by Automated Planar Patch Clamp
Cell line Cslow (pF) APA (mV) Upstroke velocity (V/s) APD (ms) APD50 (ms) APD90 (ms)
HUES7 16.8 – 3.6 83.3 – 8.5 10.5 – 2.3 369.8– 130.6 106.2 – 45.3 177.8 – 68
FIB-iPS 35.9 – 21.4 93.8 – 11.5 10.4 – 1.9 511.9– 256.8 202.7 – 139.1 282.1 – 174
BT1-iPS 22.5 – 3.8 115.1 – 18 15.1 – 3.6 417.4– 146 135.8 – 66 238.6 – 102.4
FIG. 5. Automated electrophysio-
logical analysis of HUES7 hESC-
CMs in the voltage clamp mode.
Representative raw data traces of (A)
INa, (B) ICa, and (C) IK currents in
HUES7-CMs. The maximal current
densities for the three currents were
determined to be 264.8– 9.1 pA/pF
(at220mV, n= 31),210.2–3.8 pA/
pF (at 230mV, n= 12), and
20.9– 3.6 pA/pF (at +40mV, n= 24)
respectively. (D) Averaged I/V
(current-voltage) diagrams of the INa,
ICa, and IK currents in HUES7-CMs.
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were conducted for 3min before the application of escalating
doses of their respective blockers. Peak current amplitude
was averaged from four voltage pulses for each drug con-
centration applied and for the baseline recordings. Dose–re-
sponse data were fitted to the Hill Equations and IC50 values
determined for each channel blocker tested.
TTX, a potent blocker of the INa channels, caused a
concentration-dependent inhibition of the INa current of the
hPSC-CMs, with an IC50 of 289.8 – 31.9 nM (Fig. 7A, n = 5).
Increasing concentrations of nifedipine, an L-type Ca+2
channel blocker, inhibited the current amplitude of the ICa.L
channels in a dose-dependent manner, with an IC50 of
1.4 – 1.5 mM (Fig. 7B, n = 5). Finally, E-4031—a selective
IKr (rapidly activating delayed rectifier potassium channel)
blocker—was applied to the cells in increasing doses to
check for a reduction in total IK. A concentration-dependent
inhibition of the IK current was observed and an IC50 of
2 – 1.4 mM was calculated (Fig. 7C, n = 5). Thus, this feasi-
bility study showed the suitability of the Patchliner APC
system for the electrophysiological and pharmacological
analyses of hPSC-CMs.
Discussion
In this study, we demonstrated the potential of the Pat-
chliner planar patch clamp platform for hPSC-CM-based
medium-throughput drug safety and efficacy testing. To
achieve this, we developed a cell preparation protocol that
allowed the dissociation of EB and monolayer cultures of
cardiomyocytes into single cells, while maintaining their
viability and membrane integrity. When analyzed on the
Patchliner, the freshly dissociated cardiomyocytes demon-
strated AP generation, depolarizing Na+ and Ca+2 currents,
and repolarizing K+ currents, proving their suitability for use
in disease modeling and high-throughput drug screening.
In conventional patch clamping the cell is accessed by
means of a glass pipette that is manually brought into contact
with its membrane [38], while in planar patch clamp the
traditional glass pipette is replaced by a hole at the bottom of
a well through which an applied negative pressure patches the
cell membrane [30]. This allows automation of the patch
clamp process that reduces the time and labor costs associated
with conventional patch clamp, and parallelization that dras-
tically improves screening efficiency and data output [29].
Today there exist several APC platforms, including the
IonWork Quattro (MDS), PatchXpress (Molecular Devices
Corporation), Patchliner (Nanion), SynchroPatch (Nanion),
QPatch (Sophion), and Flyscreen (Flyion), differing in their
technical specifications and level of automation [29]. In-
itially developed for the analysis of recombinant cell lines
used for heterologous channel expression, these are only
now starting to be trialled for use with more ‘‘complex’’
cells like stem cell-derived cardiomyocytes [31,37,40] and
neurons [37,41].
Cell preparation is a key factor in the performance of an
APC device, as it has a direct impact on catch rates, seal
Table 6. Current Densities of Human Pluripotent Stem Cell-Cardiomyocytes
as Determined by Automated Planar Patch Clamp
Current (test voltage)
Current density (pA/pF)
HUES7-hESC FIB-iPS BT1-iPS CP1-iPS DMD4-iPS DMD16-iPS
Na (-20mV) -64.8 – 9.1 -32.5– 16.1 -37.3 – 8.9 -25.4– 9.4 -32.9– 6.4 -19.6 – 4.5
Ca (-30mV) -10.2 – 3.8 n.d. -22.3 – 3.3 n.d. -12.8– 2.4 n.d.
K (40mV) 20.9 – 3.6 12.2– 4.1 22.5 – 6.1 40.3– 6.4 34.3– 5.6 29.4 – 6.2
DMD, Duchenne muscular dystrophy; hESCs, human embryonic stem cells; n.d., not determined.
FIG. 6. A comparison of the electrophysiological properties of hPSC-CMs using the Patchliner. Box plots demonstrating
the distribution of (A) INa, (B) ICa, and (C) IK current maxima, at220,230, and +40mV respectively, across six hPSC lines.
These cell lines included HUES7-fibroblast-derived ‘‘healthy’’ FIB-hiPSCs, dental pulp-derived BT1-hiPSCs, Duchenne
muscular dystrophy (DMD)-afflicted DMD4- and DMD6-hiPSCs, catecholaminergic polymorphic ventricular tachycardia
(CPVT)-afflicted CP1-hiPSCs, and ‘‘healthy’’ HUES7-hESCs. The maximal current densities were shown to range from
219.6 – 4.5 pA/pF to 237.3 – 8.9 pA/pF, 212.8 – 2.4 pA/pF to 222.3 – 3.3 pA/pF, and 12.2 – 4.1 pA/pF to 40.3 – 6.4 pA/pF
for INa, ICa, and IK respectively. Error bars represent standard error of mean (n = 5 for each cell line).
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qualities and observed current characteristics. Specifically,
these systems require high-density, homogenous, single-cell
suspensions for optimal performance [29]. Conventional
APC systems, like the QPatch [40] and the PatchExpress
[31], use between 8,000 and 150,000 PSC-CMs per re-
cording site at a density of 0.5–5 million cells/mL. Such
high cell numbers are required to maximize the probability
of positioning a cell over the recording aperture, and in
many cases increases in catch rates have been shown to
positively correlate with increases in cell densities [42].
With recent improvements in cardiac differentiation
protocols, hPSC-CMs can be produced in large numbers, but
with high reagent/labor costs. To illustrate, the loading of 48
recording wells of an APC, at a density of 150,000 cells/
well, would require 7.2 million cells at a cost of USD$7,200
when purchasing them from a commercial source. To reduce
costs we used a specially developed ‘‘cell stacking’’ pro-
tocol that reduces cell usage to 300–2,000 cells/recording
site [37], making it more economical for use in the high-
throughput screening of hPSC-CMs.
To obtain single-cell suspensions, cardiomyocytes cul-
tures are usually dissociated with enzymes like trypsin, as
gentler nonenzymatic harvest protocols produce cell clus-
ters that block recording sites, lowering the productivity of
the system. However, trypsin has been previously shown to
induce proteome alterations of mammalian cell mem-
branes, with a subset of these proteins remaining dysre-
gulated even after a 24 h recovery in fresh culture media
[36]. Trypsin has also been shown to affect the integrity of
membrane phospholipids [43], which could lead to reduced
catch rates, low seal resistances, and poor channel activity.
In conventional patch clamp, cells are typically seeded onto
coverslips following dissociation, and kept in culture for at
least 72 h before use [38], which gives them time to recover
from enzyme treatment. However, in case of APC, cells are
analyzed, in suspension, within a few hours of dissociation
and so the dissociation protocol used strongly impacts
seal rates and observed current outputs.
In this study, we overcame these problems by developing
a two-step cell dissociation protocol. First, intact EB/
monolayer cultures of hPSC-CMs were dissociated into
single cells using a trypsin-based dissociation method, and
then reseeded at low densities onto gelatine-coated tissue-
culture plastic. Next, following a week of recovery in cul-
ture, the attached single cells were reharvested using a
gentle and rapid accutase-assisted cold dissociation protocol
for immediate analysis on the Patchliner. This two-step
protocol yielded catch rates of 81.25%– 6.68% and seal
resistances of up to 2GO, which are a considerable im-
provement over previous studies using APC devices like the
PatchXpress that reported seal resistances of up to only
200MO using iCell hiPSC-CMs [31].
The cardiomyocytes used in our experiments were de-
rived by both the monolayer and EB-routes. Regular manual
patch clamp analysis was used to first validate the suitability
of the cardiomyocytes for further use. These experiments
revealed atrial-, nodal-, and ventricular-like APs based
on generally accepted classification criteria [15,21]. Com-
pared with adult human cardiomyocytes, our cells have
hyperpolarized RMPs, low upstroke velocities, smaller
APAs, and shorter APs. This is indicative of a fetal/neonatal
phenotype and appears to be characteristic of hPSC-CMs
[14,16,31,34].
When making automated recordings from our hPSC-CMs
in current clamp mode, we found spontaneously beating
cells to show erratic beat patterns that were unsuitable for
analysis. This could be due to the cells being in suspension
and at 4C immediately before analysis. Though this insta-
bility could be controlled by the use of stimulation proto-
cols, we found that different hPSC-CMs displayed different
stimulation thresholds. This meant each well required the
individual definition of stimulatory conditions, which de-
tracted from the automated nature of the platform. Thus, we
would suggest that data collection from hPSC-CMs on the
FIG. 7. Efficient pharmacological screening of hPSC-CMs
by automated planar patch clamp. Patch clamp analysis
showing dose-dependent inhibition of the (A) INa, (B) ICa, and
(C) IK currents, in hPSC-CMs, on treatment with increasing
concentrations of TTX, nifedipine, and terfenadine respec-
tively. IC50 values of 289.8– 31.9 nM, 1.4– 1.5mM, and
2– 1.4mM were calculated for TTX, nifedipine, and E-4031
respectively. Error bars represent standard deviation of the
mean (n= 5 for each drug).
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Patchliner platform is most effective in voltage clamp rather
than current clamp mode. We also found the cells to express
higher APAs and lower RMPs using APC, which could be
due to differences in ionic conditions, temperatures, and
holding potentials between the two platforms.
On automated voltage clamp analysis, our hPSC-CMs dis-
played current densities and activation kinetics similar to that
of other hPSC-CMs and fetal/neonatal cardiomyocytes. They
also predictably responded to the three ion channel blockers
used in the study. However, our voltage clamp experiments did
not include the recording of cellular APs beforehand to allow
for data classification into atrial-, ventricular-, and nodal-like
subtypes. This could explain the wide variations in current
densities within the same line. Further studies also need to be
performed to identify whether the observed inter-line varia-
tions in current densities is due to differences in the expression
of ion channels, or due to the presence of the channels in
different conductance states.
It is important to note that when comparing our data with
the existing literature, we found big differences in ionic
conditions, experimental protocols, tissue heterogeneity, and
disease status across studies [31,44–49], which raises the
question whether results are reproducible across research
groups [50]. Nevertheless, currently available high-efficiency
cardiac differentiation protocols [12,34] in concert with the
high-content screening abilities of APCs provide a platform
for reliable and efficient drug candidate safety profiling and
efficacy testing in industrial and academic settings.
In conclusion, this study compared the electrophysiolog-
ical properties of cardiomyocytes derived from six different
hPSC lines on an APC system. We presented an optimized
cell preparation protocol that markedly improved the pro-
ductivity of the Patchliner when using hPSC-CMs, thus
making APC recordings compatible with the study of ex-
pensive and heterogeneous cell preparations. This will
substantially enhance the feasibility of using APC platforms
for drug development using hPSC-CMs.
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